Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer
Erika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Breast Cancer Research and Treatment
|
February 5, 2013
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
Sally Anne Garnett, Miguel Martin, Guy Jerusalem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, et al.
Clinical and Translational Science
|
January 21, 2026
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Andy Sykes, Helena Engman, Nigel Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
John F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.
ESMO Open
|
January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1
C Vaklavas, M Oliveira, A C Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
E Hamilton, M Oliveira, N Turner, et al.
The Lancet. Oncology
|
October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2019
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer
Erika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Breast Cancer Research and Treatment
|
February 5, 2013
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
Sally Anne Garnett, Miguel Martin, Guy Jerusalem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, et al.
Clinical and Translational Science
|
January 21, 2026
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Andy Sykes, Helena Engman, Nigel Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
John F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.
ESMO Open
|
January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1
C Vaklavas, M Oliveira, A C Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
E Hamilton, M Oliveira, N Turner, et al.
The Lancet. Oncology
|
October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2019
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
Page
of 3